David Snyder

TL;DR: The finding that RNA transcribed in vitro from cDNA cloned in a bacterial plasmid was highly effective in sensitizing DC shows that amplification of the antigenic content from a small number of tumor cells is feasible, thus expanding the potential use of RNA-pulsed DC- based vaccines for patients bearing very small, possibly microscopic, tumors.

TL;DR: It is shown that a single immunization with DC pulsed with OVA peptide was highly effective in eliciting a protective immune response against a challenge with tumor cells expressing the OVA gene, and that in vivo priming of CTL and induction of antitumor immunity by bone marrow-generated DC also require the presentation of MHC class II-restricted epitopes and activation of CD4+ T cells.

TL;DR: If long-term safety is confirmed, NiCords has the potential to broaden accessibility and reduce the toxicity of UCB transplantation, and the results justify further study of NiCord transplantation as a single UCB graft.

TL;DR: The CTL and immunotherapy data from the two murine tumor systems suggest that APC (in particular DC) pulsed with unfractionated cell extracts as a source of tumor antigen may be equally or more effective than genetically modified tumor vaccines.

TL;DR: The results of the human studies provide basis for using halofuginone treatment for dermal fibrosis and as a first step toward future treatment of internal organ involvement, an oral administration study was performed in which halofUGinone was well tolerated and plasma levels surpassed the predicted therapeutic exposure.